BMY vs. ZTS, PFE, ABBV, MRK, JNJ, REGN, VRTX, GSK, SNY, and TAK
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), GSK (GSK), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical preparations" industry.
Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Bristol-Myers Squibb presently has a consensus target price of $60.71, indicating a potential upside of 34.01%. Zoetis has a consensus target price of $218.00, indicating a potential upside of 38.46%. Given Zoetis' stronger consensus rating and higher possible upside, analysts plainly believe Zoetis is more favorable than Bristol-Myers Squibb.
Zoetis has a net margin of 27.43% compared to Bristol-Myers Squibb's net margin of 17.83%. Zoetis' return on equity of 51.25% beat Bristol-Myers Squibb's return on equity.
In the previous week, Bristol-Myers Squibb had 54 more articles in the media than Zoetis. MarketBeat recorded 76 mentions for Bristol-Myers Squibb and 22 mentions for Zoetis. Zoetis' average media sentiment score of 0.75 beat Bristol-Myers Squibb's score of 0.10 indicating that Zoetis is being referred to more favorably in the news media.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.3%. Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.1%. Bristol-Myers Squibb pays out 62.2% of its earnings in the form of a dividend. Zoetis pays out 34.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.1% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Bristol-Myers Squibb has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Bristol-Myers Squibb received 183 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.76% of users gave Zoetis an outperform vote while only 66.91% of users gave Bristol-Myers Squibb an outperform vote.
Summary
Zoetis beats Bristol-Myers Squibb on 15 of the 20 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
